Mesenchymal Stem Cells And Differentiated Insulin Producing Cells Are New Horizons For Pancreatic Regeneration In Type I Diabetes Mellitus | 99207
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mesenchymal stem cells and differentiated insulin producing cells are new horizons for pancreatic regeneration in type I diabetes mellitus

Joint Event on 13th International Conference on Pediatric Gastroenterology Hepatology & Nutrition & 3rd International Conference on Digestive and Metabolic Diseases

Nermin Raafat

Zagazig University, Egypt

ScientificTracks Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X-C7-082

Background: Diabetes mellitus has become the third human killer following cancer and cardiovascular disease. Millions of patients, often children, suffer from type 1 diabetes (T1D). Stem cells created hopes to regenerate damaged body tissues and restore their function. Aim: This work aimed at clarifying and comparing the therapeutic potential of differentiated and non-differentiated mesenchymal stem cells (MSCs) as a new line of therapy for T1D. Methods: 40 female albino rats divided into Group I (control): 10 rats and group II (diabetic), III and IV, 10 rats in each, were injected with streptozotocin (50mg/kg body weight). Group III (MSCs) were transplanted with bone marrow derived MSCs from male rats and group IV (IPCs) with differentiated insulin producing cells. Blood and pancreatic tissue samples were taken from all rats for biochemical and histological studies. Results: MSCs reduced hyperglycemia in diabetic rats on day 15 while IPCs normalizes blood glucose level on day 7. Histological and morphometric analysis of pancreas of experimental diabetic rats showed improvement in MSCs-treated group but in IPCs-treated group, ?-cells insulin immunoreactions were obviously returned to normal, with normal distribution of ?-cells in the centre and other cells at the periphery. Meanwhile, most of the pathological lesions were still detected in diabetic rats. Conclusion: MSCs transplantation can reduce blood glucose level in recipient diabetic rats. IPCs initiate endogenous pancreatic regeneration by neogenesis of islets. IPCs are better than MSCs in regeneration of ?-cells. So, IPCs therapy can be considered clinically to offer a hope for patients suffering from T1D.

Nermin Raafat completed my MD-PhD at age of 36 from Basel University, Switzerland. I'm an assistant professor of Medical Biochemistry and Molecular Biology at Zagazig University School of Medicine, Egypt. I'm the director of Molecular Biology and Cell Culture Lab at the department, Head of Cell culture unit of Scientific and Medical Research centre, the director of Project Management Unit, the admin of Institutional Review Board and a member of Scientific research council at Zagazig University School of Medicine, Egypt. I've published more than 30 papers in reputed journals and participated in more than 30 in ternational conferences.

E-mail: [email protected]